Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 7:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 813 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Hyperactivity Disorder, Schizophrenia, Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 120 Years
Enrollment
4,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Control Condition, Intervention Condition
Interventions
Collaborative Life Skills dHealth tool (CLS-D)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
7 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CLONICEL (Clonidine HCl sustained release)
Drug
Lead sponsor
Shionogi
Industry
Eligibility
6 Years to 17 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 23 more
Conditions
Obsessive Compulsive Disorder, Body Dysmorphic Disorder, Tourette Syndrome, Trichotillomania, Panic Disorder, Social Phobia, Generalized Anxiety Disorder, Depression, Post-Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder, Eating Disorder, Specific Phobia, General Medical Condition
Interventions
Cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Neurofeedback, Cognitive Training, Waitlist Control
Behavioral · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810 (18 mg), SPN-810 (36 mg), Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
28
States / cities
Rogers, Arkansas • Culver City, California • Glendale, California + 22 more
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more
Completed Not applicable Interventional Results available

Trigeminal Nerve Stimulation for ADHD

NCT02155608
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Active eTNS, Sham eTNS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 12 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

NCT00330434
Conditions
Alcohol Drinking, Depression, Smoking Cessation, Attention Deficit Disorder
Interventions
Trial Withdrawn 1, Trial Withdrawn 2
Other
Lead sponsor
Tufts University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Autism Spectrum Disorder, Attention Deficit-Hyperactivity Disorder, Executive Function
Interventions
Unstuck and on Target (UOT), Parents and Teachers Supporting Students (PATSS)
Behavioral
Lead sponsor
Lauren Kenworthy
Other
Eligibility
8 Years to 11 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Cognitive behavioral therapy, Drug therapy
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Substance Abuse
Interventions
Adderall
Drug
Lead sponsor
Jeffrey Newcorn
Other
Eligibility
7 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
48
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 43 more
Conditions
ADHD
Interventions
Focalin XR
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Las Vegas, Nevada
Completed Phase 2 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder

NCT01692782
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
SEP-225289, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Irvine, California + 28 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADZENYS XR-ODT, Placebo Oral Tablet
Drug
Lead sponsor
Aytu BioPharma, Inc.
Industry
Eligibility
4 Years to 5 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mobile Behavioral Parent Training (mBPT), Just-in-time intervention: Parenting Strategies
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 12 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional Results available

Neuroimaging of Diet in ADHD: Phase I

NCT01862484
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Restricted Diet, Ruse Diet
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
9 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Extension and Behavior of Young Children

NCT03446716
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Sleep Extension
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
6 Years to 9 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Amherst, Massachusetts
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Zolpidem (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey